Influence of related donor age on outcomes after peripheral blood stem cell transplantation

References

• Artz AS. Comorbidity and beyond: pre-transplant clinical assessment. Bone Marrow Transplant. 2005;36:473–4.
   Google Scholar
• Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, . Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996; 36:601–10.
   PubMed Web of Science ®Google Scholar
• Bolan CD, Hartzman RJ, Perry EH, Trainor L, Miller J, Miller R, . Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14:23–8.
   PubMedGoogle Scholar
• Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, . Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001; 344:175–81.
   PubMed Web of Science ®Google Scholar
• Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, . Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98: 2043–51.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, . High-resolution donor–recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–83.
   PubMed Web of Science ®Google Scholar
• Dominietto A, Lamparelli T, Raiola AM, Van Lint MT, Gualandi F, Berisso G, . Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:3930–4.
   PubMed Web of Science ®Google Scholar
• Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98:2900–8.
   PubMed Web of Science ®Google Scholar
• Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, . Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005;89:229–35.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Ladaique P, Lemarie C, Furst S, Faucher C, Blaise D, . Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin. Blood. 2009;113: 1868–9.
   Google Scholar
• Richa E, Papari M, Allen J, Martinez G, Wickrema A, Anastasi J, . Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2009;15:1394–9.
   Google Scholar
• Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, . Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008;112:2092–100.
   PubMedGoogle Scholar
• Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A, . Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99:2726–33.
   Google Scholar
• Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, . Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009;114:2606–16.
   Web of Science ®Google Scholar
• Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, . CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98:3221–7.
   PubMed Web of Science ®Google Scholar
• Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC, . Marrow harvesting from normal donors. Blood. 1984;64:630–4.
   PubMed Web of Science ®Google Scholar
• Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, . Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transplant. 2007;13:1233–43.
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, . Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23: 5728–38.
   PubMed Web of Science ®Google Scholar
• O’Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, . Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010; 51:2240–9.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15: 825–8.
   PubMed Web of Science ®Google Scholar
• Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J Royal Stat Soc Series A. 1972;135:185–206.
   Web of Science ®Google Scholar
• StataCorp. Stata Statistical Software, 11.0 edn. College Station, TX: Stata Corp.; 2009.
   Google Scholar
• McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, . Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010; 28:1878–87.
   PubMed Web of Science ®Google Scholar
• Lysak D, Koza V, Jindra P. Factors affecting PBSC mobilization and collection in healthy donors. Transfus Apher Sci. 2005;33:275–83.
   Google Scholar
• Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl- Goldstein KE, Johnston LJ, . CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol. 2005;33: 279–85.
   Google Scholar
• Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH, . Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia. 2003;17: 869–75.
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C, . Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood. 2003;102:1108–13.
   PubMed Web of Science ®Google Scholar
• Diez-Campelo M, Perez-Simon JA, Ocio EM, Castilla C, Gonzalez-Porras JR, Sanchez-Guijo FM, . CD34+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Leuk Lymphoma. 2005;46:177–83.
   PubMed Web of Science ®Google Scholar
• Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, . Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Biol Blood Marrow Transplant. 2004;10:448–60.
   Google Scholar
• Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, Chakraverty R, . The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol. 2005;140:540–6.
   PubMed Web of Science ®Google Scholar
• Panse JP, Heimfeld S, Guthrie KA, Maris MB, Maloney DG, Baril BB, . Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol. 2005;128:659–67.
   PubMed Web of Science ®Google Scholar
• Pang WW, Price EA, Sahoo D, Beerman I, Maloney WJ, Rossi DJ, . Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA. 2011;108:20012–7.
   PubMed Web of Science ®Google Scholar
• Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, . Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28:405–11.
   PubMed Web of Science ®Google Scholar